NN Investment Partners Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

NN Investment Partners Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$29.9M	Buy	114,469 +33,337	+41%	+$7.91M	0.16%	120
2021 Q4	$17.8M	Sell	81,132 -25,080	-24%	-$4.88M	0.09%	197
2021 Q3	$19.3M	Buy	106,212 +6,512	+7%	+$1.27M	0.11%	164
2021 Q2	$20.1M	Sell	99,700 -15,087	-13%	-$3.16M	0.11%	166
2021 Q1	$24.7M	Sell	114,787 -15,138	-12%	-$3.33M	0.15%	135
2020 Q4	$30.7M	Sell	129,925 -29,463	-18%	-$6.76M	0.19%	98
2020 Q3	$43.4M	Sell	159,388 -81,301	-34%	-$22.4M	0.28%	72
2020 Q2	$69.9M	Sell	240,689 -53,713	-18%	-$14.6M	0.47%	45
2020 Q1	$70.1M	Buy	294,402 +11,619	+4%	+$2.67M	0.57%	38
2019 Q4	$61.9M	Buy	282,783 +109,620	+63%	+$22.2M	0.42%	51
2019 Q3	$29.3M	Buy	173,163 +134,420	+347%	+$23.8M	0.23%	97
2019 Q2	$7.11M	Buy	38,743 +3,479	+10%	+$608K	0.06%	268
2019 Q1	$6.49M	Buy	35,264 +526	+2%	+$97.2K	0.05%	283
2018 Q4	$5.76M	Buy	34,738 +405	+1%	+$70.2K	0.05%	262
2018 Q3	$6.62M	Sell	34,333 -2,901	-8%	-$517K	0.05%	255
2018 Q2	$6.33M	Buy	37,234 +5,964	+19%	+$924K	0.05%	254
2018 Q1	$5.1M	Sell	31,270 -25,460	-45%	-$4.16M	0.04%	310
2017 Q4	$8.5M	Sell	56,730 -22,000	-28%	-$3.26M	0.06%	231
2017 Q3	$11.3M	Buy	78,730 +51,236	+186%	+$7.71M	0.07%	229
2017 Q2	$3.54M	Sell	27,494 -659	-2%	-$79.3K	0.03%	282
2017 Q1	$3.08M	Buy	28,153 +2,610	+10%	+$230K	0.03%	291
2016 Q4	$1.88M	Sell	25,543 -6,250	-20%	-$509K	0.02%	368
2016 Q3	$2.77M	Buy	31,793 +3,700	+13%	+$350K	0.03%	314
2016 Q2	$2.42M	Sell	28,093 -1,270	-4%	-$110K	0.02%	332
2016 Q1	$2.33M	Buy	+29,363	New	+$2.66M	0.02%	326

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

NN Investment Partners Holdings's VRTX Position: Q1 2022 in Review

NN Investment Partners Holdings increased its Vertex Pharmaceuticals (VRTX) stake by 41% in Q1 2022, buying an estimated $7.91M and bringing the position to 114,469 shares worth $29.9M. The position accounts for 0.16% of the portfolio, ranked #120.

NN Investment Partners Holdings first reported a position in VRTX in Q1 2016 and has held it in 25 quarters since. The position peaked at $70.1M in Q1 2020. 1,072 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

NN Investment Partners Holdings held 114,469 shares of Vertex Pharmaceuticals worth $29.9M as of Q1 2022.
NN Investment Partners Holdings bought 33,337 Vertex Pharmaceuticals shares in Q1 2022, an estimated $7.91M.
Vertex Pharmaceuticals made up 0.16% of NN Investment Partners Holdings's portfolio in Q1 2022, its #120 holding.
NN Investment Partners Holdings first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 25 quarters since.
NN Investment Partners Holdings's Vertex Pharmaceuticals position peaked at $70.1M in Q1 2020.
1,072 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on NN Investment Partners Holdings's 13F filing for Q1 2022, filed 11 May 2022.